ORIC amendment: Point72 group reports 0% stake
Oric Pharmaceuticals filed an Amendment No. 1 to a Schedule 13G/A reporting that Point72-affiliated filers hold 0% of the class.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Oric Pharmaceuticals filed an Amendment No. 1 to a Schedule 13G/A reporting that Point72-affiliated filers hold 0% of the class. The cover-page figures are stated as of the close of business on March 31, 2026. The amendment lists Point72 Asset Management, Point72 Capital Advisors, Inc., and Steven A. Cohen as reporting persons and provides a principal business address.
Insights
Amendment confirms no beneficial ownership by Point72 group as of March 31, 2026.
The filing amends a Schedule 13G/A to state that the reported entities (Point72 Asset Management, Point72 Capital Advisors, and Steven A. Cohen) beneficially own 0% of Oric Pharmaceuticals' common stock as of March 31, 2026. The cover-page Row 9 references are incorporated by reference.
Cash‑flow treatment and share counts are not provided in the excerpt; subsequent filings would be needed for changes in position or transaction details.
Key Figures
Key Terms
Schedule 13G/A regulatory
beneficially owned regulatory
cover page Row 9 regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did ORIC's Schedule 13G/A amendment disclose about Point72's holdings?
Who are the reporting persons named in the ORIC amendment?
What date anchors the ownership figures in the ORIC filing?
Does the amendment list any voting or dispositive power for the reporting persons?
AI-generated analysis. How Rhea-AI works. Not financial advice.